BioSyent Balance Sheet Health
Financial Health criteria checks 6/6
BioSyent has a total shareholder equity of CA$34.8M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$41.5M and CA$6.8M respectively. BioSyent's EBIT is CA$7.5M making its interest coverage ratio -7. It has cash and short-term investments of CA$26.2M.
Key information
0%
Debt to equity ratio
CA$0
Debt
| Interest coverage ratio | -7x |
| Cash | CA$26.19m |
| Equity | CA$34.76m |
| Total liabilities | CA$6.77m |
| Total assets | CA$41.53m |
Recent financial health updates
No updates
Recent updates
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues
Mar 22
BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045
Feb 09BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price
Apr 14BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 19Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?
Mar 17BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year
Feb 18
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative
Jan 28BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate
Jan 07BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 17Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?
Dec 02Financial Position Analysis
Short Term Liabilities: RX's short term assets (CA$35.9M) exceed its short term liabilities (CA$5.5M).
Long Term Liabilities: RX's short term assets (CA$35.9M) exceed its long term liabilities (CA$1.2M).
Debt to Equity History and Analysis
Debt Level: RX is debt free.
Reducing Debt: RX has not had any debt for past 5 years.
Debt Coverage: RX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: RX has no debt, therefore coverage of interest payments is not a concern.